Latest News and Press Releases

Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal...

LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1...

CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...

CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...

CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic...

Objectifs de recrutement dépassés avec 1.009 patients randomisés dans la cohorte principale et 411 dans la cohorte exploratoirePrincipaux résultats de NATiV3 attendus au deuxième semestre 2026 et, si...

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A...

Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024Levée d’un produit brut de 116 millions d’euros dans le...